Recce Pharmaceuticals Ltd RCE-AU:ASX
*Data is delayed | Exchange | AUD
Last | 06/03/26 AET
0.52UNCH (UNCH)
52 week range
0.29 - 0.73
- Open0.00
- Day High0.00
- Day Low0.00
- Prev Close0.52
- 52 Week High0.73
- 52 Week High Date01/15/26
- 52 Week Low0.29
- 52 Week Low Date06/24/25
Latest On Recce Pharmaceuticals Ltd
Key Stats
- Market Cap150.375M
- Shares Out289.18M
- 10 Day Average Volume0.13M
- Dividend-
- Dividend Yield-
- Beta0.31
Latest On Recce Pharmaceuticals Ltd
KEY STATS
- Open0.00
- Day High0.00
- Day Low0.00
- Prev Close0.52
- 52 Week High0.73
- 52 Week High Date01/15/26
- 52 Week Low0.29
- 52 Week Low Date06/24/25
- Market Cap150.375M
- Shares Out289.18M
- 10 Day Average Volume0.13M
- Dividend-
- Dividend Yield-
- Beta0.31
RATIOS/PROFITABILITY
- EPS (TTM)-0.09
- P/E (TTM)-5.66
- Fwd P/E (NTM)-
- EBITDA (TTM)-26.262M
- ROE (TTM)-
- Revenue (TTM)1.133M
- Gross Margin (TTM)-
- Net Margin (TTM)-2,670.63%
- Debt To Equity (MRQ)-56.06%
EVENTS
- Earnings Date-
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
There is no recent news for this security.
Related Video
watch now
Profile
MORERecce Pharmaceuticals Ltd is an Australia-based company. The Company is engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of...
John Prendergast
Independent Non- Executive Chairman of the Board
James Graham
Chief Executive Officer, Managing Director, Executive Director
Justin Reynolds
Chief Financial Officer
Philip Sutton
Vice President of Translational Sciences
Address
Level 23
180 George St, Salesforce Tower
Sydney, NSW
2000
Australia